Last reviewed · How we verify

Civacir® 10% — Competitive Intelligence Brief

Civacir® 10% (Civacir® 10%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hepatitis C immunoglobulin (HCV-IG). Area: Immunology / Infectious Disease.

phase 3 Hepatitis C immunoglobulin (HCV-IG) Hepatitis C virus (HCV) envelope proteins Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Civacir® 10% (Civacir® 10%) — Biotest Pharmaceuticals Corporation. Civacir is a hepatitis C immunoglobulin (HCV-IG) that provides passive immunity by supplying antibodies against hepatitis C virus to prevent reinfection in transplant recipients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Civacir® 10% TARGET Civacir® 10% Biotest Pharmaceuticals Corporation phase 3 Hepatitis C immunoglobulin (HCV-IG) Hepatitis C virus (HCV) envelope proteins

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hepatitis C immunoglobulin (HCV-IG) class)

  1. Biotest Pharmaceuticals Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Civacir® 10% — Competitive Intelligence Brief. https://druglandscape.com/ci/civacir-10. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: